[Duration of effective hypoglycaemic action of glipizide given once daily (author's transl)].
The clinically effective duration of blood glucose lowering action of a new hypoglycaemic sulphonylurea, glipizide, given in single before breakfast dosage (up to 20 mg) has been studied in 20 apparently insulin-independent diabetics. All, on diet only, had persistent overnight 1-2% glycosuria, fasting glycaemia in excess of 150 mg/100ml, random mid-morning glycaemia of at least 250 mg/100ml and associated clinical symptoms. Eighteen were satisfactorily controlled over the observation period of six months by single daily dosage (mean 10 mg daily); in addition considerable improvement in glucose tolerance occurred. Complementary in-patients indicated that, within the range of dosage studied, there was no therapeutic advantage in taking glipizide twice daily.
D000284:Administration, Oral; D000368:Aged; D001682:Biological Availability; D001786:Blood Glucose / Q000378:metabolism; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D005913:Glipizide / Q000008:administration & dosage*; D005951:Glucose Tolerance Test; D006029:Glycosuria / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*
D001786:Blood Glucose; D007328:Insulin; D013453:Sulfonylurea Compounds; D005913:Glipizide
Wirkungsdauer von Tageseinzeldosen Glipizid bei Diabetes mellitus